News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,708 Results
Type
Article (779)
Company Profile (18)
Press Release (12910)
Multimedia
Podcasts (2)
Webinars (2)
Section
Business (4499)
Career Advice (17)
Deals (654)
Drug Delivery (2)
Drug Development (2335)
Employer Resources (2)
FDA (222)
Job Trends (277)
News (7250)
Policy (383)
Tag
Academia (37)
Accelerated approval (2)
Adcomms (5)
Allergies (6)
Alliances (1217)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (20)
Approvals (216)
Artificial intelligence (7)
Autoimmune disease (6)
Bankruptcy (4)
Best Places to Work (219)
BIOSECURE Act (5)
Biosimilars (1)
Biotechnology (14)
Bladder cancer (1)
Brain cancer (1)
Breast cancer (2)
Cancer (123)
Cardiovascular disease (12)
Career advice (10)
CAR-T (16)
CDC (1)
Cell therapy (56)
Clinical research (1878)
Collaboration (63)
Compensation (34)
Complete response letters (4)
COVID-19 (103)
CRISPR (7)
C-suite (42)
Cystic fibrosis (1)
Data (169)
Diabetes (13)
Diagnostics (32)
Drug discovery (9)
Drug pricing (1)
Earnings (1499)
Editorial (2)
Employer resources (2)
Events (2533)
Executive appointments (51)
FDA (294)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (48)
Gene editing (13)
Gene therapy (38)
GLP-1 (19)
Government (52)
Guidances (7)
Healthcare (388)
Immunology and inflammation (13)
Immuno-oncology (1)
Infectious disease (105)
Inflammatory bowel disease (10)
Intellectual property (6)
Interviews (3)
IPO (363)
Job creations (62)
Job search strategy (10)
JPM (2)
Kidney cancer (1)
Labor market (5)
Layoffs (20)
Legal (65)
Liver cancer (2)
Lung cancer (16)
Lymphoma (21)
Machine learning (1)
Management (1)
Manufacturing (29)
MASH (2)
Medical device (66)
Medtech (66)
Mergers & acquisitions (320)
Metabolic disorders (21)
Neurodegenerative disease (8)
Neuroscience (27)
NextGen: Class of 2026 (139)
Non-profit (20)
Now hiring (1)
Obesity (6)
Opinion (1)
Ovarian cancer (4)
Pain (9)
Pancreatic cancer (2)
Parkinson's disease (5)
Patents (11)
Patient recruitment (9)
People (1757)
Pharmacy benefit managers (1)
Phase 1 (855)
Phase 2 (919)
Phase 3 (541)
Pipeline (145)
Policy (14)
Postmarket research (25)
Preclinical (285)
Press Release (1)
Prostate cancer (3)
Psychedelics (1)
Radiopharmaceuticals (2)
Rare diseases (38)
Real estate (115)
Recruiting (1)
Regulatory (384)
Reports (3)
Research institute (63)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (12)
Series B (4)
Service/supplier (1)
Sickle cell disease (2)
Special edition (2)
Spinal muscular atrophy (1)
Sponsored (2)
Startups (105)
Supply chain (2)
Tariffs (2)
The Weekly (2)
Vaccines (16)
Venture capital (4)
Weight loss (3)
Date
Today (3)
Last 7 days (16)
Last 30 days (54)
Last 365 days (818)
2026 (78)
2025 (838)
2024 (1024)
2023 (1263)
2022 (1597)
2021 (1628)
2020 (1242)
2019 (736)
2018 (543)
2017 (663)
2016 (546)
2015 (592)
2014 (397)
2013 (340)
2012 (293)
2011 (296)
2010 (310)
Location
Africa (16)
Asia (1125)
Australia (91)
California (504)
Canada (123)
China (36)
Colorado (3)
Connecticut (9)
Delaware (14)
Europe (1315)
Florida (33)
Idaho (1)
Illinois (7)
India (9)
Indiana (2)
Japan (16)
Maryland (64)
Massachusetts (226)
Michigan (4)
Minnesota (6)
Nevada (1)
New Jersey (73)
New Mexico (1)
New York (40)
North Carolina (18)
Northern California (222)
Oklahoma (1)
Pennsylvania (69)
South America (9)
Southern California (191)
Texas (38)
United States (1105)
Utah (2)
Virginia (1)
Washington D.C. (2)
Washington State (17)
Wisconsin (2)
13,708 Results for "salubris biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Salubris Biotherapeutics Provides Updates on JK07 and JK06 Clinical Programs
September 29, 2025
·
6 min read
Press Releases
Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
October 20, 2025
·
4 min read
Drug Development
Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
Salubris Biotherapeutics, Inc. today announced a new capital infusion of $35 million to fund continued research and development of clinical and pre-clinical programs.
April 22, 2024
·
6 min read
Press Releases
Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure
January 22, 2025
·
4 min read
BioCapital
Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
Salubris Biotherapeutics, Inc. announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.
March 28, 2023
·
4 min read
Press Releases
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
January 27, 2026
·
5 min read
Press Releases
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
January 29, 2026
·
8 min read
Drug Development
Salubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the completed Phase 1b study of JK07 in patients with HFrEF.
October 9, 2023
·
4 min read
BioCapital
Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced that positive initial data from the first-in-human study evaluating JK08 in adults with solid tumors were presented in a poster session during the European Society of Medical Oncology Annual Congress 2023.
October 23, 2023
·
3 min read
Press Releases
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
January 12, 2026
·
7 min read
1 of 1,371
Next
